Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats

Transplantation

Volumn 84, Issue 4, 2007, Pages 517-526

  Onuta, Geanina ^a   Rienstra, Heleen ^a   De Boer, Jan Freark ^a   Boer, Mark Walther ^a   Roks, Anton J M ^a   Klatter, Flip A ^a   Uges, Donald R A ^a   Navis, Gerjan ^a   Rozing, Jan ^a   Hillebrands, Jan Luuk ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

PPAR ; Rat; Rosiglitazone; Smooth muscle cells; Transplant arteriosclerosis

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; ROSIGLITAZONE; STROMAL CELL DERIVED FACTOR 1ALPHA;

ALLOIMMUNITY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA GRAFT; ARTERIOSCLEROSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FLOW CYTOMETRY; GENE EXPRESSION; LYMPHOCYTE; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECIPIENT; REGULATORY T LYMPHOCYTE;

ANIMALS; AORTA, ABDOMINAL; ARTERIOSCLEROSIS; CELL PROLIFERATION; CHEMOKINES, CXC; FORKHEAD TRANSCRIPTION FACTORS; MALE; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; RATS; RATS, INBRED BN; RATS, INBRED LEW; RATS, INBRED WF; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; T-LYMPHOCYTES, REGULATORY; THIAZOLIDINEDIONES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548189537     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000276983.91892.99     Document Type: Article

References (45)

1. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation-how much of the promise has been realized? Nat Med 2005; 11: 605.
2. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14: 387.
3. Hillebrands JL, Onuta G, Rozing J. Role of progenitor cells in transplant arteriosclerosis. Trends Cardiovasc Med 2005; 15: 1.
4. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421.
5. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106.
6. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52.
7. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004; 43: 297.
8. van Wijk JP, Rabelink TJ. PPAR-gamma agonists: Shifting attention from the belly to the heart? Arterioscler Thromb Vasc Biol 2004; 24: 798.
9. Kosuge H, Haraguchi G, Koga N, et al. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 2006; 113: 2613.
10. Hillebrands JL, Klatter FA, van den Hurk BM, et al. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107: 1411.
11. Jefferies WA, Green JR, Williams AF. Authentic T helper CD4 (W3/25) antigen on rat peritoneal macrophages. J Exp Med 1985; 162: 117.
12. Duijvestijn AM, van Goor H, Klatter F, et al. Antibodies defining rat endothelial cells: RECA-1, a pan-endothelial cell-specific monoclonal antibody. Lab Invest 1992; 66: 459.
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
14. Campbell JH, Campbell GR. Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci 1993; 85: 501.
15. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000; 164: 1364.
16. Hillebrands JL, Klatter FA, van Dijk WD, Rozing J. Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat Med 2002; 8: 194.
17. Hillebrands JL, Klatter FA, Rozing J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 380.
18. Hillebrands J, van den Hurk BM, Klatter FA, et al. Recipient origin of neointimal vascular smooth muscle cells in cardiac allografts with transplant arteriosclerosis. J Heart Lung Transplant 2000; 19: 1183.
19. Sakihama H, Masunaga T, Yamashita K, et al. Stromal cell-derived factor-1 and CXCR4 interaction is critical for development of transplant arteriosclerosis. Circulation 2004; 110: 2924.
20. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004; 15: 237.
21. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897.
22. Shinohara E, Kihara S, Ouchi N, et al. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 1998; 136: 275.
23. Yoshimoto T, Naruse M, Shizume H, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999; 145: 333.
24. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930.
25. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867.
26. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168.
27. Law RE, Goetze S, Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311.
28. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79.
29. Bishop-Bailey D, Hla T, Warner TD. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res 2002; 91: 210.
30. Lim S, Jin CJ, Kim M, et al. PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 2006; 26: 808.
31. Tontonoz P, Nagy L, Alvarez JG, et al. PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241.
32. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001; 357: 33.
33. Hannan KM, Dilley RJ, de Dios ST, Little PJ. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol 2003; 23: 762.
34. Harris SG, Phipps RP. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001; 31: 1098.
35. Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator- activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002; 8: 330.
36. Cobbold SP, Adams E, Graca L et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol Rev 2006; 213: 239.
37. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007; 178: 2940.
38. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 2007; 178: 4129.
39. Bruemmer D, Law RE. Thiazolidinedione regulation of smooth muscle cell proliferation. Am J Med 2003; 115 Suppl 8A: 87S.
40. Bruemmer D, Yin F, Liu J, et al. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ Res 2003; 93: e38.
41. Artwohl M, Furnsinn C, Waldhausl W, et al. Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma- independent mechanism. Diabetologia 2005; 48: 586.
42. Turturro F, Oliver Iii RE, Friday E, et al. Troglitazone and Pioglitazone interactions via PPAR{gamma} independent and dependent pathways in regulating physiological responses in renal tubule derived cell lines. Am J Physiol Cell Physiol 2007; 292: 1137.
43. Chawla A, Barak Y, Nagy L, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48.
44. Voytovich MH, Simonsen C, Jenssen T, et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 413.
45. Pietruck F, Kribben A, Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 2005; 18: 483.